SNOA
Sonoma Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.12
+0.00%Oct 6, 2026, 20:35 UTC
Sonoma Pharmaceuticals entered into a Section 382 Rights Agreement providing one preferred stock purchase right for each common share, with each right exercisable for one one-thousandth of a Series B Preferred share at $10.00, subject to adjustment.
Aug 6, 2026, 12:33 UTC
Sonoma Pharmaceuticals Inc. reported its first-quarter financial results, achieving record quarterly revenue and turning EBITDA positive for the first time, with a net loss of 9 cents per share compared to a loss of 76 cents per share a year earlier.